Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$6.7 - $12.0 $2.52 Million - $4.51 Million
376,000 Added 6.87%
5,845,956 $55.2 Million
Q4 2023

Feb 14, 2024

SELL
$3.18 - $6.86 $1.11 Million - $2.39 Million
-348,848 Reduced 6.0%
5,469,956 $36.9 Million
Q3 2023

Nov 14, 2023

SELL
$3.25 - $6.08 $797,286 - $1.49 Million
-245,319 Reduced 4.05%
5,818,804 $25.8 Million
Q2 2023

Aug 14, 2023

BUY
$2.26 - $3.8 $1.25 Million - $2.1 Million
552,284 Added 10.02%
6,064,123 $20 Million
Q1 2023

May 15, 2023

BUY
$2.83 - $13.99 $1.47 Million - $7.25 Million
518,560 Added 10.39%
5,511,839 $15.7 Million
Q4 2022

Feb 14, 2023

BUY
$5.01 - $8.35 $5.05 Million - $8.41 Million
1,007,369 Added 25.27%
4,993,279 $36.4 Million
Q3 2022

Nov 14, 2022

BUY
$4.92 - $9.1 $121,602 - $224,915
24,716 Added 0.62%
3,985,910 $32.2 Million
Q2 2022

Aug 15, 2022

BUY
$4.2 - $24.0 $1.47 Million - $8.4 Million
350,000 Added 9.69%
3,961,194 $19.4 Million
Q1 2022

May 16, 2022

SELL
$9.96 - $23.65 $2.55 Million - $6.05 Million
-255,678 Reduced 6.61%
3,611,194 $85.4 Million
Q4 2021

Feb 14, 2022

BUY
$14.0 - $28.44 $162,134 - $329,363
11,581 Added 0.3%
3,866,872 $68.4 Million
Q3 2021

Nov 15, 2021

BUY
$7.28 - $30.97 $4.73 Million - $20.1 Million
650,000 Added 20.28%
3,855,291 $109 Million
Q1 2021

May 14, 2021

BUY
$10.94 - $15.32 $12.4 Million - $17.4 Million
1,133,882 Added 54.74%
3,205,291 $37.8 Million
Q4 2020

Feb 16, 2021

BUY
$7.84 - $13.4 $7.22 Million - $12.3 Million
920,844 Added 80.03%
2,071,409 $24.3 Million
Q3 2020

Nov 16, 2020

BUY
$7.22 - $20.7 $8.31 Million - $23.8 Million
1,150,565 New
1,150,565 $9.12 Million

Others Institutions Holding FULC

About Fulcrum Therapeutics, Inc.


  • Ticker FULC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,038,900
  • Market Cap $237M
  • Description
  • Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...
More about FULC
Track This Portfolio

Track Rtw Investments, LP Portfolio

Follow Rtw Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rtw Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Rtw Investments, LP with notifications on news.